NEW YORK, Oct. 22, 2020 /PRNewswire/ -- Seelos
Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage
biopharmaceutical company focused on the development of therapies
for central nervous system disorders and rare diseases, today
announced that it will participate in two investor conferences in
November.
Seelos Therapeutics' senior management will participate in:
- Jefferies Virtual Global Healthcare Conference,
Tuesday-Thursday, November 17-19
- Benchmark Virtual Discovery One on One Investor Conference,
Wednesday, November 18
Raj Mehra, Ph.D., Chairman and CEO and Dr. Tim Whitaker, MD, Head of Research and
Development, will host 1x1 meetings via conference calls.
About Seelos Therapeutics:
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical
company focused on the development and advancement of novel
therapeutics to address unmet medical needs for the benefit of
patients with central nervous system (CNS) disorders and other rare
diseases. The Company's robust portfolio includes several
late-stage clinical assets targeting indications including Acute
Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder
(MDD) or Post-Traumatic Stress Disorder (PTSD), Amyotrophic
lateral sclerosis (ALS), Sanfilippo syndrome, Parkinson's Disease,
other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website:
http://seelostherapeutics.com, the content of which is not
incorporated herein by reference.
Contact Information:
Anthony Marciano
Head of Corporate Communications
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Ave., 12th Fl
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
View original content to download
multimedia:http://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-investor-conferences-in-november-301157408.html
SOURCE Seelos Therapeutics, Inc.